Genome-wide associations with metabolic syndrome among UK Biobank participants reporting use of second-generation antipsychotics.

ABSTRACT:

Objectives

Second-generation antipsychotic (SGA) medications are frequently prescribed for mental health conditions; however, they are associated with an increased risk of metabolic syndrome (MetS). We aimed to identify genetic associations of SGA-associated MetS (SGA-MetS) using genome-wide approaches within the UK Biobank. We also set out to evaluate if genetically predicted obesity is associated with an increased risk of SGA-MetS.

Methods

We defined SGA-MetS based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria using cross-sectional data from 1318 UK Biobank participants who reported being on an SGA medication. An SGA-MetS case was defined as meeting three or more of the five NCEP-ATP III criteria. We performed a genome-wi

SUBMITTER: Rouby NE 

PROVIDER: S-EPMC12340748 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature